Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Результаты исследования влияния фитогормонов экстракта цимицифуги на структурно-функциональные показатели кожи в перименопаузе, менопаузе и постменопаузе
Результаты исследования влияния фитогормонов экстракта цимицифуги на структурно-функциональные показатели кожи в перименопаузе, менопаузе и постменопаузе
Юцковская Я.А., Суханова А.С.
Результаты исследования влияния фитогормонов экстракта цимицифуги на структурно-функциональные показатели кожи в перименопаузе, менопаузе и постменопаузе. Гинекология. 2015; 17 (6): 4–10.
Результаты исследования влияния фитогормонов экстракта цимицифуги на структурно-функциональные показатели кожи в перименопаузе, менопаузе и постменопаузе. Гинекология. 2015; 17 (6): 4–10.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Представлены результаты изучения эффективности и безопасности совместного применения лекарственного средства Ци-Клим (производитель фармацевтическая компания «Эвалар», Россия) и косметического средства Ци-Клим, содержащих экстракт цимицифуги, с целью коррекции структурно-функциональных изменений кожи у женщин в периоде перименопаузы, менопаузы и постменопаузы.
Материалы и методы. Под наблюдением находились 15 женщин в возрасте от 41 до 56 лет, имевшие какие-либо признаки климактерического синдрома. Проводились исследование морфофункциональных характеристик кожи (в том числе измерение толщины дермы и эпидермиса с помощью ультразвука, характеристика структуры, влажности, эластичности и внешнего вида кожи), а также оценка качества жизни с помощью опросника SF-36. Лекарственное средство Ци-Клим назначалось по 1 таблетке 2 раза в сутки внутрь во время приема пищи в течение 12 мес, крем Ци-Клим рекомендовалось наносить на кожу лица по 1 мл 2 раза в день ежедневно в течение 12 мес. Повторные осмотры проводились ежемесячно, оценка морфофункциональных характеристик кожи – через 6 и 12 мес.
Результаты. Через 6 и 12 мес у пациенток отмечались значимое уменьшение толщины эпидермиса и увеличение толщины дермы, повышение увлажненности и эластичности кожи. Улучшались внешние характеристики кожи и как результат – качество жизни женщин.
Вывод. Совместное применение лекарственного средства Ци-Клим и косметического средства Ци-Клим на основе растительного сырья – высокоэффективно, отличается безопасностью и хорошей переносимостью, позволяет добиться хорошего результата в лечении инволюционных изменений кожи, улучшает психоэмоциональное состояние и качество жизни женщин.
Ключевые слова: климактерический синдром, кожа, цимицифуга, фитоэстрогены, лекарственное средство Ци-Клим.
Materials and methods. Under supervision there were 15 women aged from 41 till 56 years, who had any signs of a climacteric syndrome. Research of the morphologic and functional skin characteristics (including measurement of thickness of derma and epidermis by means of ultrasound, the characteristic of structure, humidity, elasticity and visual appearance of skin), and also an assessment of quality of life by means of SF-36 questionnaire was conducted. Patients were treated with combination of medicine Ci-Clim 1 tablet 2 times per day during meal within 12 months, and cosmetic product Ci-Clim on the face (1 ml 2 times a day) daily within 12 months. Repeated visits were performed monthly, an assessment of the morphological and functional properties of the skin were done at 6 and 12 months.
Results. Significant reduction of thickness of epidermis and increase in thickness of derma, and also increase of skin humidity and elasticity were noted at 6 and 12 months. Visual characteristics of skin improved. Quality of life of postmenopausal women improved as well as the skin characteristics.
Conclusion. Application of the combination of medicine Ci-Clim and cosmetic product Ci-Clim, containing herbal extracts is highly effective, safe and well tolerated drug that allows to achieve effect in treatment of involutional changes of skin, improving an emotional state and quality of life of women.
Key words: Ci-Clim, climacteric syndrome, skin, cimicifuga, phytoestrogens.
Материалы и методы. Под наблюдением находились 15 женщин в возрасте от 41 до 56 лет, имевшие какие-либо признаки климактерического синдрома. Проводились исследование морфофункциональных характеристик кожи (в том числе измерение толщины дермы и эпидермиса с помощью ультразвука, характеристика структуры, влажности, эластичности и внешнего вида кожи), а также оценка качества жизни с помощью опросника SF-36. Лекарственное средство Ци-Клим назначалось по 1 таблетке 2 раза в сутки внутрь во время приема пищи в течение 12 мес, крем Ци-Клим рекомендовалось наносить на кожу лица по 1 мл 2 раза в день ежедневно в течение 12 мес. Повторные осмотры проводились ежемесячно, оценка морфофункциональных характеристик кожи – через 6 и 12 мес.
Результаты. Через 6 и 12 мес у пациенток отмечались значимое уменьшение толщины эпидермиса и увеличение толщины дермы, повышение увлажненности и эластичности кожи. Улучшались внешние характеристики кожи и как результат – качество жизни женщин.
Вывод. Совместное применение лекарственного средства Ци-Клим и косметического средства Ци-Клим на основе растительного сырья – высокоэффективно, отличается безопасностью и хорошей переносимостью, позволяет добиться хорошего результата в лечении инволюционных изменений кожи, улучшает психоэмоциональное состояние и качество жизни женщин.
Ключевые слова: климактерический синдром, кожа, цимицифуга, фитоэстрогены, лекарственное средство Ци-Клим.
________________________________________________
Materials and methods. Under supervision there were 15 women aged from 41 till 56 years, who had any signs of a climacteric syndrome. Research of the morphologic and functional skin characteristics (including measurement of thickness of derma and epidermis by means of ultrasound, the characteristic of structure, humidity, elasticity and visual appearance of skin), and also an assessment of quality of life by means of SF-36 questionnaire was conducted. Patients were treated with combination of medicine Ci-Clim 1 tablet 2 times per day during meal within 12 months, and cosmetic product Ci-Clim on the face (1 ml 2 times a day) daily within 12 months. Repeated visits were performed monthly, an assessment of the morphological and functional properties of the skin were done at 6 and 12 months.
Results. Significant reduction of thickness of epidermis and increase in thickness of derma, and also increase of skin humidity and elasticity were noted at 6 and 12 months. Visual characteristics of skin improved. Quality of life of postmenopausal women improved as well as the skin characteristics.
Conclusion. Application of the combination of medicine Ci-Clim and cosmetic product Ci-Clim, containing herbal extracts is highly effective, safe and well tolerated drug that allows to achieve effect in treatment of involutional changes of skin, improving an emotional state and quality of life of women.
Key words: Ci-Clim, climacteric syndrome, skin, cimicifuga, phytoestrogens.
Полный текст
Список литературы
1. Calleja-Agius J, Muscat-Baron Y, Brincat MP. Skin ageing. Menopause Int. 2007; 13 (2): 60–4.
2. Brincat MP. Hormone Replacement Therapy and the Skin. Lancaster: Parthenon, 2001.
3. Hall GK, Phillips TJ. Skin and hormone therapy. Clin Obstet Gynecol 2004; 47: 437–49.
4. Brincat MP, Baron YM, Galea R. Estrogens and the skin. Climacteric 2005; 8 (2): 110–23.
5. Brincat M, Moniz CF, Kabalan S et al. Decline in skin collagen content and metacarpal index after the menopause and its prevention with sex hormone replacement. Br J Obstet Gynaecol 1987; 94 (2): 126–9.
6. Castelo-Branco C, Duran M, González-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas 1992; 15 (2): 113–9.
7. Shah MG, Maibach HI. Estrogen and skin. An overview. Am J Clin Dermatol 2001; 2 (3): 143–50.
8. Shuster S. Osteoporosis, a unitary hypothesis of collagen loss in skin and bone. Med Hypotheses 2005; 65 (3): 426–32.
9. Bolognia JL, Braverman IM, Rousseau ME, Sarrel PM. Skin changes in menopause.Maturitas 1989; 11 (4): 295–304.
10. Savvas M, Bishop J, Laurent G et al. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. Br J Obstet Gynaecol 1993; 100 (2): 154–6.
11. Schmidt JB, Binder M, Demschik G et al. Treatment of skin aging with topical estrogens.Int J Dermatol 1996; 35 (9): 669–74.
12. Varila E, Rantala I, Oikarinen A et al. The effect of topical oestradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995; 102 (12): 985–9.
13. Punnonen R, Vaajalahti P, Teisala K. Local oestriol treatment improves the structure of elastic fibers in the skin of postmenopausal women Ann Chir Gynaecol Suppl 1987; 202: 39–41.
14. Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (II): protein, glycosaminoglycan, water, and lipid content and structure. Skin Res Technol 2006; 12 (3): 145–54.
15. Sator PG, Schmidt JB, Sator MO et al. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas 2001; 39 (1): 43–55.
16. Maheux R, Naud F, Rioux M et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994; 170 (2): 642–9.
17. Sumino H, Ichikawa S, Abe M et al. Effects of aging, menopause, and hormone replacement therapy on forearm skin elasticity in women. J Am Geriatr Soc 2004; 52 (6): 945–9.
18. Piérard GE, Letawe C, Dowlati A, Piérard-Franchimont C. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995; 43 (6): 662–5.
19. Castelo-Branco C, Figueras F, de Osaba MJM, Vanrell JA. Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy. Maturitas 1998; 29 (1): 75–86.
20. Haenggi W, Linder HR, Birkhaeuser MH, Schneider H. Microscopic findings of the nail-fold capillaries – dependence on menopausal status and hormone replacement therapy. Maturitas. 199; 22 (1): 37–46.
21. Arora S, Veves A, Caballaro AE et al. Estrogen improves endothelial function. J Vasc Surg 1998; 27 (6): 1141–6; discussion 1147.
22. Nair PA. Dermatosis associated with menopause. J Midlife Health 2014; 5 (4): 168–75.
23. Клинические рекомендации. Акушерство и гинекология. Под ред. В.Н.Серова, Г.Т.Сухих. Изд. 4-е, перераб. и доп. М.: ГЭОТАР-Медиа, 2014. / Klinicheskie rekomendacii. Akusherstvo i ginekologija. Pod red. V.N.Serova, G.T.Suhih. Izd. 4-e, pererab. i dop. M.: GJeOTAR-Media, 2014. [in Russian]
24. Wines N, Willsteed E. Menopause and the skin. Australas J Dermatol 2001; 42 (3): 149–8; quiz. 159.
25. Лорен С. Женщины и красота. М.: Вагриус, 2001. / Loren S. Zhenshchiny i krasota. M.: Vagrius, 2001. [in Russian]
26. Antiaging Products and Services: The Global Market. BCC Research, 2013 – 164 pages. Интернет-ресурс http://www.bccresearch.com/ market-research/healthcare/antiaging-products-services-hlc060b.html. Дата обращения 21.06.2015. / Antiaging Products and Services: The Global Market. BCC Research, 2013 – 164 pages. Internet resource http://www.bccresearch.com/market-research/ healthcare/antiaging-products-services-hlc060b.html. Date accessed 21 Jun 2015. [in Russian]
27. Foster S. Black cohosh: Cimicifuga racemosa: a literature review. Herbalgram. 1999; 45: 35–49.
28. Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol 2005; 4 (3): 177–84.
29. Грицюк М. 50 плюс новая жизнь. «Российская газета» – Федеральный вып. №5622 (246) Интернет-ресурс http://www.rg.ru/ 2011/11/02/trud.html. Дата обращения 21.06.2015. / Gricjuk M. 50 pljus novaja zhizn'. "Rossijskaja gazeta" – Federal'nyj vyp. №5622 (246) Internet-resource http://www.rg.ru/ 2011/11/02/trud.html. Date accessed 21 Jun 2015. [in Russian]
30. García-Pérez MA, Pineda B, Hermenegildo C et al. Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line. Fertil Steril. 2009; 91 (Suppl. 4): 1347–50.
31. Stoll W. Phytotherapeutikum beeinflusst atrophisches Vaginalepithel: Doppelblind-versuch Cimicifuga vs. Ostrogenpraparat. Therapeutikon 1987; 1: 23–31.
32. Lehmann-Willenbrock E, Riedel HH. Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa. Zentralbl Gynakol 1988; 110 (10): 611–8.
33. Warnecke G. Influencing menopausal symptoms with a phytotherapeutic agent. Med Welt 1985; 36: 871–4.
34. Liske E, Hänggi W, Henneicke-von Zepelin HH et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002; 11 (2): 163–74.
35. Daiber W. Klimakterische beschwerden: ohne hormone zum erfolg. Ӓrztliche Praxis 1983; 35: 1946–7.
36. Pethӧ A. Klimakterische beschwerden: umstellung einer hormonbehandlung auf ein pflanzliches gynӓkologikum mӧglich? Ӓrztliche Praxis 1987; 38: 1551–3
37. Chen J, Gao H, Li Q et al. Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone. Zhonghua Yi Xue Za Zhi 2013; 93 (8): 600–2.
38. Huang YX, Song L, Zhang X et al. Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression. Zhonghua Yi Xue Za Zhi 2013; 93 (8): 600–2.
39. Juliá Mollá MD, García-Sánchez Y, Romeu Sarri A et al. Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women. Gynecol Endocrinol 2009; 25 (1): 21–6.
40. Ross SM. Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms. Holist Nurs Pract 2012; 26 (1): 58–61.
41. Drewe J, Zimmermann C, Zahner C. The effect of a Cimicifuga racemosa extracts Ze 450 in the treatment of climacteric complaints – an observational study. Phytomedicine. 2013; 20 (8–9): 659–66.
42. Ayres DC, Loike JD. Lignans. Chemical, biological and clinical properties. Eds. J.D.Phillllipson, D.C.Ayres, H.Baxter. Chemistry & Pharmacology of Natural Products. Cambridge: University Press, 1990.
43. Ботоева Е.А. К вопросу о фитоэстрогенах (обзор литературы). Бюллетень ВСНЦ СО РАМН. 2010. Гинекология. 2013; 15 (1): 85–92. / Botoeva E.A. K voprosu o fitojestrogenah (obzor literatury). Bjulleten' VSNC SO RAMN. 2010. Gynecology. 2013; 15 (1): 85–92. [in Russian]
44. Кузнецова И.В. Растительные препараты в климактерии: многообразие и разумный выбор. Эффективная фармакотерапия. 2011; 2: 50–4. / Kuznecova I.V. Rastitel'nye preparaty v klimakterii: mnogoobrazie i razumnyj vybor. Jeffektivnaja farmakoterapija. 2011; 2: 50-4. [in Russian]
45. Кузнецова И.В., Успенская Ю.Б. Применение фитоэстрогенов у женщин в период менопаузального перехода и постменопаузе. Эффективная фармакотерапия. 2013; 52: 44–51. / Kuznecova I.V., Uspenskaja Ju.B. Primenenie fitojestrogenov u zhenshhin v period menopauzal'nogo perehoda i postmenopauze. Jeffektivnaja farmakoterapija. 2013; 52: 44–51. [in Russian]
46. Reame NE, Lukacs JL, Padmanabhan V et al. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 2008; 15 (5): 832–40.
47. Иванова О.В., Усольцева Е.Н., Брюхина Е.В. Клиническая эффективность и динамика качества жизни у женщин с климактерическим синдромом, принимающих фитоэстрогены. Мед. наука и образ. Урала; 2013. 14 (1): 22–5. / Ivanova O.V., Usol'ceva E.N.,
Brjuhina E.V. Klinicheskaja jeffektivnost' i dinamika kachestva zhizni u zhenshhin s klimaktericheskim sindromom, prinimajushhih fitojestrogeny. Med. nauka i obraz. Urala; 2013. 14 (1): 22–5. [in Russian]
48. Татарова Н.А., Линде В.А., Жидкова Е.В., Сохадзе Х.С. Негормональная коррекция климактерических расстройств в пери- и постменопаузе. Эффективная фармакотерапия. 2009; 17: 12–5. / Tatarova N.A., Linde V.A., Zhidkova E.V., Sohadze H.S. Negormonal'naja korrekcija klimaktericheskih rasstrojstv v peri- i postmenopauze. Jeffektivnaja farmakoterapija. 2009; 17: 12–5. [in Russian]
49. Moreira AC, Silva AM, Santos MS, Sardão VA. Phytoestrogens as alternative hormone replacement therapy in menopause: What is real, what is unknown. J Steroid Biochem Mol Biol 2014; 143: 61–71.
50. Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric 2015; 18 (2): 260–9.
51. Инструкция по медицинскому применению препарата Ци-клим, ЗАО «Эвалар», Россия. Регистрационное удостоверение № ЛСР-006592/09.
52. Ehrlich M, Rao J, Pabby A, Goldman MP. Improvement in the appearance of wrinkles with topical transforming growth factor beta(1) and l-ascorbic acid. Dermatol Surg 2006; 32 (5): 618–25.
2. Brincat MP. Hormone Replacement Therapy and the Skin. Lancaster: Parthenon, 2001.
3. Hall GK, Phillips TJ. Skin and hormone therapy. Clin Obstet Gynecol 2004; 47: 437–49.
4. Brincat MP, Baron YM, Galea R. Estrogens and the skin. Climacteric 2005; 8 (2): 110–23.
5. Brincat M, Moniz CF, Kabalan S et al. Decline in skin collagen content and metacarpal index after the menopause and its prevention with sex hormone replacement. Br J Obstet Gynaecol 1987; 94 (2): 126–9.
6. Castelo-Branco C, Duran M, González-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas 1992; 15 (2): 113–9.
7. Shah MG, Maibach HI. Estrogen and skin. An overview. Am J Clin Dermatol 2001; 2 (3): 143–50.
8. Shuster S. Osteoporosis, a unitary hypothesis of collagen loss in skin and bone. Med Hypotheses 2005; 65 (3): 426–32.
9. Bolognia JL, Braverman IM, Rousseau ME, Sarrel PM. Skin changes in menopause.Maturitas 1989; 11 (4): 295–304.
10. Savvas M, Bishop J, Laurent G et al. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. Br J Obstet Gynaecol 1993; 100 (2): 154–6.
11. Schmidt JB, Binder M, Demschik G et al. Treatment of skin aging with topical estrogens.Int J Dermatol 1996; 35 (9): 669–74.
12. Varila E, Rantala I, Oikarinen A et al. The effect of topical oestradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995; 102 (12): 985–9.
13. Punnonen R, Vaajalahti P, Teisala K. Local oestriol treatment improves the structure of elastic fibers in the skin of postmenopausal women Ann Chir Gynaecol Suppl 1987; 202: 39–41.
14. Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (II): protein, glycosaminoglycan, water, and lipid content and structure. Skin Res Technol 2006; 12 (3): 145–54.
15. Sator PG, Schmidt JB, Sator MO et al. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas 2001; 39 (1): 43–55.
16. Maheux R, Naud F, Rioux M et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994; 170 (2): 642–9.
17. Sumino H, Ichikawa S, Abe M et al. Effects of aging, menopause, and hormone replacement therapy on forearm skin elasticity in women. J Am Geriatr Soc 2004; 52 (6): 945–9.
18. Piérard GE, Letawe C, Dowlati A, Piérard-Franchimont C. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995; 43 (6): 662–5.
19. Castelo-Branco C, Figueras F, de Osaba MJM, Vanrell JA. Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy. Maturitas 1998; 29 (1): 75–86.
20. Haenggi W, Linder HR, Birkhaeuser MH, Schneider H. Microscopic findings of the nail-fold capillaries – dependence on menopausal status and hormone replacement therapy. Maturitas. 199; 22 (1): 37–46.
21. Arora S, Veves A, Caballaro AE et al. Estrogen improves endothelial function. J Vasc Surg 1998; 27 (6): 1141–6; discussion 1147.
22. Nair PA. Dermatosis associated with menopause. J Midlife Health 2014; 5 (4): 168–75.
23. Klinicheskie rekomendacii. Akusherstvo i ginekologija. Pod red. V.N.Serova, G.T.Suhih. Izd. 4-e, pererab. i dop. M.: GJeOTAR-Media, 2014. [in Russian]
24. Wines N, Willsteed E. Menopause and the skin. Australas J Dermatol 2001; 42 (3): 149–8; quiz. 159.
25. Лорен С. Женщины и красота. М.: Вагриус, 2001. / Loren S. Zhenshchiny i krasota. M.: Vagrius, 2001. [in Russian]
26. Antiaging Products and Services: The Global Market. BCC Research, 2013 – 164 pages. Internet resource http://www.bccresearch.com/market research/ healthcare/antiaging-products-services-hlc060b.html. Date accessed 21 Jun 2015. [in Russian]
27. Foster S. Black cohosh: Cimicifuga racemosa: a literature review. Herbalgram. 1999; 45: 35–49.
28. Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol 2005; 4 (3): 177–84.
29. Gricjuk M. 50 pljus novaja zhizn'. "Rossijskaja gazeta" – Federal'nyj vyp. №5622 (246) Internet-resource http://www.rg.ru/ 2011/11/02/trud.html. Date accessed 21 Jun 2015. [in Russian]
30. García-Pérez MA, Pineda B, Hermenegildo C et al. Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line. Fertil Steril. 2009; 91 (Suppl. 4): 1347–50.
31. Stoll W. Phytotherapeutikum beeinflusst atrophisches Vaginalepithel: Doppelblind-versuch Cimicifuga vs. Ostrogenpraparat. Therapeutikon 1987; 1: 23–31.
32. Lehmann-Willenbrock E, Riedel HH. Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa. Zentralbl Gynakol 1988; 110 (10): 611–8.
33. Warnecke G. Influencing menopausal symptoms with a phytotherapeutic agent. Med Welt 1985; 36: 871–4.
34. Liske E, Hänggi W, Henneicke-von Zepelin HH et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002; 11 (2): 163–74.
35. Daiber W. Klimakterische beschwerden: ohne hormone zum erfolg. Ӓrztliche Praxis 1983; 35: 1946–7.
36. Pethӧ A. Klimakterische beschwerden: umstellung einer hormonbehandlung auf ein pflanzliches gynӓkologikum mӧglich? Ӓrztliche Praxis 1987; 38: 1551–3
37. Chen J, Gao H, Li Q et al. Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone. Zhonghua Yi Xue Za Zhi 2013; 93 (8): 600–2.
38. Huang YX, Song L, Zhang X et al. Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression. Zhonghua Yi Xue Za Zhi 2013; 93 (8): 600–2.
39. Juliá Mollá MD, García-Sánchez Y, Romeu Sarri A et al. Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women. Gynecol Endocrinol 2009; 25 (1): 21–6.
40. Ross SM. Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms. Holist Nurs Pract 2012; 26 (1): 58–61.
41. Drewe J, Zimmermann C, Zahner C. The effect of a Cimicifuga racemosa extracts Ze 450 in the treatment of climacteric complaints – an observational study. Phytomedicine. 2013; 20 (8–9): 659–66.
42. Ayres DC, Loike JD. Lignans. Chemical, biological and clinical properties. Eds. J.D.Phillllipson, D.C.Ayres, H.Baxter. Chemistry & Pharmacology of Natural Products. Cambridge: University Press, 1990.
43. Botoeva E.A. K voprosu o fitojestrogenah (obzor literatury). Bjulleten' VSNC SO RAMN. 2010. Gynecology. 2013; 15 (1): 85–92. [in Russian]
44. Kuznecova I.V. Rastitel'nye preparaty v klimakterii: mnogoobrazie i razumnyj vybor. Jeffektivnaja farmakoterapija. 2011; 2: 50-4. [in Russian]
45. Kuznecova I.V., Uspenskaja Ju.B. Primenenie fitojestrogenov u zhenshhin v period menopauzal'nogo perehoda i postmenopauze. Jeffektivnaja farmakoterapija. 2013; 52: 44–51. [in Russian]
46. Reame NE, Lukacs JL, Padmanabhan V et al. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 2008; 15 (5): 832–40.
47. Ivanova O.V., Usol'ceva E.N., Brjuhina E.V. Klinicheskaja jeffektivnost' i dinamika kachestva zhizni u zhenshhin s klimaktericheskim sindromom, prinimajushhih fitojestrogeny. Med. nauka i obraz. Urala; 2013. 14 (1): 22–5. [in Russian]
48. Tatarova N.A., Linde V.A., Zhidkova E.V., Sohadze H.S. Negormonal'naja korrekcija klimaktericheskih rasstrojstv v peri- i postmenopauze. Jeffektivnaja farmakoterapija. 2009; 17: 12–5. [in Russian]
49. Moreira AC, Silva AM, Santos MS, Sardão VA. Phytoestrogens as alternative hormone replacement therapy in menopause: What is real, what is unknown. J Steroid Biochem Mol Biol 2014; 143: 61–71.
50. Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric 2015; 18 (2): 260–9.
51. Инструкция по медицинскому применению препарата Ци-клим, ЗАО «Эвалар», Россия. Регистрационное удостоверение № ЛСР-006592/09.
52. Ehrlich M, Rao J, Pabby A, Goldman MP. Improvement in the appearance of wrinkles with topical transforming growth factor beta(1) and l-ascorbic acid. Dermatol Surg 2006; 32 (5): 618–25.
2. Brincat MP. Hormone Replacement Therapy and the Skin. Lancaster: Parthenon, 2001.
3. Hall GK, Phillips TJ. Skin and hormone therapy. Clin Obstet Gynecol 2004; 47: 437–49.
4. Brincat MP, Baron YM, Galea R. Estrogens and the skin. Climacteric 2005; 8 (2): 110–23.
5. Brincat M, Moniz CF, Kabalan S et al. Decline in skin collagen content and metacarpal index after the menopause and its prevention with sex hormone replacement. Br J Obstet Gynaecol 1987; 94 (2): 126–9.
6. Castelo-Branco C, Duran M, González-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas 1992; 15 (2): 113–9.
7. Shah MG, Maibach HI. Estrogen and skin. An overview. Am J Clin Dermatol 2001; 2 (3): 143–50.
8. Shuster S. Osteoporosis, a unitary hypothesis of collagen loss in skin and bone. Med Hypotheses 2005; 65 (3): 426–32.
9. Bolognia JL, Braverman IM, Rousseau ME, Sarrel PM. Skin changes in menopause.Maturitas 1989; 11 (4): 295–304.
10. Savvas M, Bishop J, Laurent G et al. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. Br J Obstet Gynaecol 1993; 100 (2): 154–6.
11. Schmidt JB, Binder M, Demschik G et al. Treatment of skin aging with topical estrogens.Int J Dermatol 1996; 35 (9): 669–74.
12. Varila E, Rantala I, Oikarinen A et al. The effect of topical oestradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995; 102 (12): 985–9.
13. Punnonen R, Vaajalahti P, Teisala K. Local oestriol treatment improves the structure of elastic fibers in the skin of postmenopausal women Ann Chir Gynaecol Suppl 1987; 202: 39–41.
14. Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (II): protein, glycosaminoglycan, water, and lipid content and structure. Skin Res Technol 2006; 12 (3): 145–54.
15. Sator PG, Schmidt JB, Sator MO et al. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas 2001; 39 (1): 43–55.
16. Maheux R, Naud F, Rioux M et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994; 170 (2): 642–9.
17. Sumino H, Ichikawa S, Abe M et al. Effects of aging, menopause, and hormone replacement therapy on forearm skin elasticity in women. J Am Geriatr Soc 2004; 52 (6): 945–9.
18. Piérard GE, Letawe C, Dowlati A, Piérard-Franchimont C. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995; 43 (6): 662–5.
19. Castelo-Branco C, Figueras F, de Osaba MJM, Vanrell JA. Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy. Maturitas 1998; 29 (1): 75–86.
20. Haenggi W, Linder HR, Birkhaeuser MH, Schneider H. Microscopic findings of the nail-fold capillaries – dependence on menopausal status and hormone replacement therapy. Maturitas. 199; 22 (1): 37–46.
21. Arora S, Veves A, Caballaro AE et al. Estrogen improves endothelial function. J Vasc Surg 1998; 27 (6): 1141–6; discussion 1147.
22. Nair PA. Dermatosis associated with menopause. J Midlife Health 2014; 5 (4): 168–75.
23. Клинические рекомендации. Акушерство и гинекология. Под ред. В.Н.Серова, Г.Т.Сухих. Изд. 4-е, перераб. и доп. М.: ГЭОТАР-Медиа, 2014. / Klinicheskie rekomendacii. Akusherstvo i ginekologija. Pod red. V.N.Serova, G.T.Suhih. Izd. 4-e, pererab. i dop. M.: GJeOTAR-Media, 2014. [in Russian]
24. Wines N, Willsteed E. Menopause and the skin. Australas J Dermatol 2001; 42 (3): 149–8; quiz. 159.
25. Лорен С. Женщины и красота. М.: Вагриус, 2001. / Loren S. Zhenshchiny i krasota. M.: Vagrius, 2001. [in Russian]
26. Antiaging Products and Services: The Global Market. BCC Research, 2013 – 164 pages. Интернет-ресурс http://www.bccresearch.com/ market-research/healthcare/antiaging-products-services-hlc060b.html. Дата обращения 21.06.2015. / Antiaging Products and Services: The Global Market. BCC Research, 2013 – 164 pages. Internet resource http://www.bccresearch.com/market-research/ healthcare/antiaging-products-services-hlc060b.html. Date accessed 21 Jun 2015. [in Russian]
27. Foster S. Black cohosh: Cimicifuga racemosa: a literature review. Herbalgram. 1999; 45: 35–49.
28. Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol 2005; 4 (3): 177–84.
29. Грицюк М. 50 плюс новая жизнь. «Российская газета» – Федеральный вып. №5622 (246) Интернет-ресурс http://www.rg.ru/ 2011/11/02/trud.html. Дата обращения 21.06.2015. / Gricjuk M. 50 pljus novaja zhizn'. "Rossijskaja gazeta" – Federal'nyj vyp. №5622 (246) Internet-resource http://www.rg.ru/ 2011/11/02/trud.html. Date accessed 21 Jun 2015. [in Russian]
30. García-Pérez MA, Pineda B, Hermenegildo C et al. Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line. Fertil Steril. 2009; 91 (Suppl. 4): 1347–50.
31. Stoll W. Phytotherapeutikum beeinflusst atrophisches Vaginalepithel: Doppelblind-versuch Cimicifuga vs. Ostrogenpraparat. Therapeutikon 1987; 1: 23–31.
32. Lehmann-Willenbrock E, Riedel HH. Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa. Zentralbl Gynakol 1988; 110 (10): 611–8.
33. Warnecke G. Influencing menopausal symptoms with a phytotherapeutic agent. Med Welt 1985; 36: 871–4.
34. Liske E, Hänggi W, Henneicke-von Zepelin HH et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002; 11 (2): 163–74.
35. Daiber W. Klimakterische beschwerden: ohne hormone zum erfolg. Ӓrztliche Praxis 1983; 35: 1946–7.
36. Pethӧ A. Klimakterische beschwerden: umstellung einer hormonbehandlung auf ein pflanzliches gynӓkologikum mӧglich? Ӓrztliche Praxis 1987; 38: 1551–3
37. Chen J, Gao H, Li Q et al. Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone. Zhonghua Yi Xue Za Zhi 2013; 93 (8): 600–2.
38. Huang YX, Song L, Zhang X et al. Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression. Zhonghua Yi Xue Za Zhi 2013; 93 (8): 600–2.
39. Juliá Mollá MD, García-Sánchez Y, Romeu Sarri A et al. Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women. Gynecol Endocrinol 2009; 25 (1): 21–6.
40. Ross SM. Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms. Holist Nurs Pract 2012; 26 (1): 58–61.
41. Drewe J, Zimmermann C, Zahner C. The effect of a Cimicifuga racemosa extracts Ze 450 in the treatment of climacteric complaints – an observational study. Phytomedicine. 2013; 20 (8–9): 659–66.
42. Ayres DC, Loike JD. Lignans. Chemical, biological and clinical properties. Eds. J.D.Phillllipson, D.C.Ayres, H.Baxter. Chemistry & Pharmacology of Natural Products. Cambridge: University Press, 1990.
43. Ботоева Е.А. К вопросу о фитоэстрогенах (обзор литературы). Бюллетень ВСНЦ СО РАМН. 2010. Гинекология. 2013; 15 (1): 85–92. / Botoeva E.A. K voprosu o fitojestrogenah (obzor literatury). Bjulleten' VSNC SO RAMN. 2010. Gynecology. 2013; 15 (1): 85–92. [in Russian]
44. Кузнецова И.В. Растительные препараты в климактерии: многообразие и разумный выбор. Эффективная фармакотерапия. 2011; 2: 50–4. / Kuznecova I.V. Rastitel'nye preparaty v klimakterii: mnogoobrazie i razumnyj vybor. Jeffektivnaja farmakoterapija. 2011; 2: 50-4. [in Russian]
45. Кузнецова И.В., Успенская Ю.Б. Применение фитоэстрогенов у женщин в период менопаузального перехода и постменопаузе. Эффективная фармакотерапия. 2013; 52: 44–51. / Kuznecova I.V., Uspenskaja Ju.B. Primenenie fitojestrogenov u zhenshhin v period menopauzal'nogo perehoda i postmenopauze. Jeffektivnaja farmakoterapija. 2013; 52: 44–51. [in Russian]
46. Reame NE, Lukacs JL, Padmanabhan V et al. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 2008; 15 (5): 832–40.
47. Иванова О.В., Усольцева Е.Н., Брюхина Е.В. Клиническая эффективность и динамика качества жизни у женщин с климактерическим синдромом, принимающих фитоэстрогены. Мед. наука и образ. Урала; 2013. 14 (1): 22–5. / Ivanova O.V., Usol'ceva E.N.,
Brjuhina E.V. Klinicheskaja jeffektivnost' i dinamika kachestva zhizni u zhenshhin s klimaktericheskim sindromom, prinimajushhih fitojestrogeny. Med. nauka i obraz. Urala; 2013. 14 (1): 22–5. [in Russian]
48. Татарова Н.А., Линде В.А., Жидкова Е.В., Сохадзе Х.С. Негормональная коррекция климактерических расстройств в пери- и постменопаузе. Эффективная фармакотерапия. 2009; 17: 12–5. / Tatarova N.A., Linde V.A., Zhidkova E.V., Sohadze H.S. Negormonal'naja korrekcija klimaktericheskih rasstrojstv v peri- i postmenopauze. Jeffektivnaja farmakoterapija. 2009; 17: 12–5. [in Russian]
49. Moreira AC, Silva AM, Santos MS, Sardão VA. Phytoestrogens as alternative hormone replacement therapy in menopause: What is real, what is unknown. J Steroid Biochem Mol Biol 2014; 143: 61–71.
50. Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric 2015; 18 (2): 260–9.
51. Инструкция по медицинскому применению препарата Ци-клим, ЗАО «Эвалар», Россия. Регистрационное удостоверение № ЛСР-006592/09.
52. Ehrlich M, Rao J, Pabby A, Goldman MP. Improvement in the appearance of wrinkles with topical transforming growth factor beta(1) and l-ascorbic acid. Dermatol Surg 2006; 32 (5): 618–25.
________________________________________________
2. Brincat MP. Hormone Replacement Therapy and the Skin. Lancaster: Parthenon, 2001.
3. Hall GK, Phillips TJ. Skin and hormone therapy. Clin Obstet Gynecol 2004; 47: 437–49.
4. Brincat MP, Baron YM, Galea R. Estrogens and the skin. Climacteric 2005; 8 (2): 110–23.
5. Brincat M, Moniz CF, Kabalan S et al. Decline in skin collagen content and metacarpal index after the menopause and its prevention with sex hormone replacement. Br J Obstet Gynaecol 1987; 94 (2): 126–9.
6. Castelo-Branco C, Duran M, González-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas 1992; 15 (2): 113–9.
7. Shah MG, Maibach HI. Estrogen and skin. An overview. Am J Clin Dermatol 2001; 2 (3): 143–50.
8. Shuster S. Osteoporosis, a unitary hypothesis of collagen loss in skin and bone. Med Hypotheses 2005; 65 (3): 426–32.
9. Bolognia JL, Braverman IM, Rousseau ME, Sarrel PM. Skin changes in menopause.Maturitas 1989; 11 (4): 295–304.
10. Savvas M, Bishop J, Laurent G et al. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. Br J Obstet Gynaecol 1993; 100 (2): 154–6.
11. Schmidt JB, Binder M, Demschik G et al. Treatment of skin aging with topical estrogens.Int J Dermatol 1996; 35 (9): 669–74.
12. Varila E, Rantala I, Oikarinen A et al. The effect of topical oestradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995; 102 (12): 985–9.
13. Punnonen R, Vaajalahti P, Teisala K. Local oestriol treatment improves the structure of elastic fibers in the skin of postmenopausal women Ann Chir Gynaecol Suppl 1987; 202: 39–41.
14. Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (II): protein, glycosaminoglycan, water, and lipid content and structure. Skin Res Technol 2006; 12 (3): 145–54.
15. Sator PG, Schmidt JB, Sator MO et al. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas 2001; 39 (1): 43–55.
16. Maheux R, Naud F, Rioux M et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994; 170 (2): 642–9.
17. Sumino H, Ichikawa S, Abe M et al. Effects of aging, menopause, and hormone replacement therapy on forearm skin elasticity in women. J Am Geriatr Soc 2004; 52 (6): 945–9.
18. Piérard GE, Letawe C, Dowlati A, Piérard-Franchimont C. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995; 43 (6): 662–5.
19. Castelo-Branco C, Figueras F, de Osaba MJM, Vanrell JA. Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy. Maturitas 1998; 29 (1): 75–86.
20. Haenggi W, Linder HR, Birkhaeuser MH, Schneider H. Microscopic findings of the nail-fold capillaries – dependence on menopausal status and hormone replacement therapy. Maturitas. 199; 22 (1): 37–46.
21. Arora S, Veves A, Caballaro AE et al. Estrogen improves endothelial function. J Vasc Surg 1998; 27 (6): 1141–6; discussion 1147.
22. Nair PA. Dermatosis associated with menopause. J Midlife Health 2014; 5 (4): 168–75.
23. Klinicheskie rekomendacii. Akusherstvo i ginekologija. Pod red. V.N.Serova, G.T.Suhih. Izd. 4-e, pererab. i dop. M.: GJeOTAR-Media, 2014. [in Russian]
24. Wines N, Willsteed E. Menopause and the skin. Australas J Dermatol 2001; 42 (3): 149–8; quiz. 159.
25. Лорен С. Женщины и красота. М.: Вагриус, 2001. / Loren S. Zhenshchiny i krasota. M.: Vagrius, 2001. [in Russian]
26. Antiaging Products and Services: The Global Market. BCC Research, 2013 – 164 pages. Internet resource http://www.bccresearch.com/market research/ healthcare/antiaging-products-services-hlc060b.html. Date accessed 21 Jun 2015. [in Russian]
27. Foster S. Black cohosh: Cimicifuga racemosa: a literature review. Herbalgram. 1999; 45: 35–49.
28. Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol 2005; 4 (3): 177–84.
29. Gricjuk M. 50 pljus novaja zhizn'. "Rossijskaja gazeta" – Federal'nyj vyp. №5622 (246) Internet-resource http://www.rg.ru/ 2011/11/02/trud.html. Date accessed 21 Jun 2015. [in Russian]
30. García-Pérez MA, Pineda B, Hermenegildo C et al. Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line. Fertil Steril. 2009; 91 (Suppl. 4): 1347–50.
31. Stoll W. Phytotherapeutikum beeinflusst atrophisches Vaginalepithel: Doppelblind-versuch Cimicifuga vs. Ostrogenpraparat. Therapeutikon 1987; 1: 23–31.
32. Lehmann-Willenbrock E, Riedel HH. Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa. Zentralbl Gynakol 1988; 110 (10): 611–8.
33. Warnecke G. Influencing menopausal symptoms with a phytotherapeutic agent. Med Welt 1985; 36: 871–4.
34. Liske E, Hänggi W, Henneicke-von Zepelin HH et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002; 11 (2): 163–74.
35. Daiber W. Klimakterische beschwerden: ohne hormone zum erfolg. Ӓrztliche Praxis 1983; 35: 1946–7.
36. Pethӧ A. Klimakterische beschwerden: umstellung einer hormonbehandlung auf ein pflanzliches gynӓkologikum mӧglich? Ӓrztliche Praxis 1987; 38: 1551–3
37. Chen J, Gao H, Li Q et al. Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone. Zhonghua Yi Xue Za Zhi 2013; 93 (8): 600–2.
38. Huang YX, Song L, Zhang X et al. Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression. Zhonghua Yi Xue Za Zhi 2013; 93 (8): 600–2.
39. Juliá Mollá MD, García-Sánchez Y, Romeu Sarri A et al. Cimicifuga racemosa treatment and health related quality of life in post-menopausal Spanish women. Gynecol Endocrinol 2009; 25 (1): 21–6.
40. Ross SM. Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms. Holist Nurs Pract 2012; 26 (1): 58–61.
41. Drewe J, Zimmermann C, Zahner C. The effect of a Cimicifuga racemosa extracts Ze 450 in the treatment of climacteric complaints – an observational study. Phytomedicine. 2013; 20 (8–9): 659–66.
42. Ayres DC, Loike JD. Lignans. Chemical, biological and clinical properties. Eds. J.D.Phillllipson, D.C.Ayres, H.Baxter. Chemistry & Pharmacology of Natural Products. Cambridge: University Press, 1990.
43. Botoeva E.A. K voprosu o fitojestrogenah (obzor literatury). Bjulleten' VSNC SO RAMN. 2010. Gynecology. 2013; 15 (1): 85–92. [in Russian]
44. Kuznecova I.V. Rastitel'nye preparaty v klimakterii: mnogoobrazie i razumnyj vybor. Jeffektivnaja farmakoterapija. 2011; 2: 50-4. [in Russian]
45. Kuznecova I.V., Uspenskaja Ju.B. Primenenie fitojestrogenov u zhenshhin v period menopauzal'nogo perehoda i postmenopauze. Jeffektivnaja farmakoterapija. 2013; 52: 44–51. [in Russian]
46. Reame NE, Lukacs JL, Padmanabhan V et al. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 2008; 15 (5): 832–40.
47. Ivanova O.V., Usol'ceva E.N., Brjuhina E.V. Klinicheskaja jeffektivnost' i dinamika kachestva zhizni u zhenshhin s klimaktericheskim sindromom, prinimajushhih fitojestrogeny. Med. nauka i obraz. Urala; 2013. 14 (1): 22–5. [in Russian]
48. Tatarova N.A., Linde V.A., Zhidkova E.V., Sohadze H.S. Negormonal'naja korrekcija klimaktericheskih rasstrojstv v peri- i postmenopauze. Jeffektivnaja farmakoterapija. 2009; 17: 12–5. [in Russian]
49. Moreira AC, Silva AM, Santos MS, Sardão VA. Phytoestrogens as alternative hormone replacement therapy in menopause: What is real, what is unknown. J Steroid Biochem Mol Biol 2014; 143: 61–71.
50. Chen MN, Lin CC, Liu CF. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review. Climacteric 2015; 18 (2): 260–9.
51. Инструкция по медицинскому применению препарата Ци-клим, ЗАО «Эвалар», Россия. Регистрационное удостоверение № ЛСР-006592/09.
52. Ehrlich M, Rao J, Pabby A, Goldman MP. Improvement in the appearance of wrinkles with topical transforming growth factor beta(1) and l-ascorbic acid. Dermatol Surg 2006; 32 (5): 618–25.
Авторы
Я.А.Юцковская*1, А.С.Суханова2
1. «Клиника профессора Юцковской». 105118, Россия, Москва, пр-т Буденного, д. 26, корп. 1;
2. ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*yutskovskaya@yandex.ru
1. Clinic professor Yutskovskaya. 105118, Russian Federation, Moscow, pr-t Budennogo, d. 26, korp. 1;
2. N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*yutskovskaya@yandex.ru
1. «Клиника профессора Юцковской». 105118, Россия, Москва, пр-т Буденного, д. 26, корп. 1;
2. ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*yutskovskaya@yandex.ru
________________________________________________
1. Clinic professor Yutskovskaya. 105118, Russian Federation, Moscow, pr-t Budennogo, d. 26, korp. 1;
2. N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*yutskovskaya@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.